Loading…
Treatment with somatostatin analogs induces differentially expressed let-7c-5p and mir-3137 in small intestine neuroendocrine tumors
Distant metastases frequently occur in gastroenteropancreatic neuroendocrine tumors. If hepatic surgery is not feasible, patients are treated with somatostatin analogs. However, the underlying mechanisms of action of this treatment remain to be defined. The aim of the present study was to analyze th...
Saved in:
Published in: | BMC cancer 2019-06, Vol.19 (1), p.575-575, Article 575 |
---|---|
Main Authors: | , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c625t-1b29dbc20e82918056166c233d8a035d61322eaee929c032f7bca944b4ac8ee33 |
---|---|
cites | cdi_FETCH-LOGICAL-c625t-1b29dbc20e82918056166c233d8a035d61322eaee929c032f7bca944b4ac8ee33 |
container_end_page | 575 |
container_issue | 1 |
container_start_page | 575 |
container_title | BMC cancer |
container_volume | 19 |
creator | Bösch, Florian Bazhin, Alexandr V Heublein, Sabine Brüwer, Katharina Knösel, Thomas Reiter, Florian P Auernhammer, Christoph J Guba, Markus O Spitzweg, Christine Werner, Jens Angele, Martin K |
description | Distant metastases frequently occur in gastroenteropancreatic neuroendocrine tumors. If hepatic surgery is not feasible, patients are treated with somatostatin analogs. However, the underlying mechanisms of action of this treatment remain to be defined. The aim of the present study was to analyze the micro-RNA expression profile inter-individually before and after the treatment with somatostatin analogs.
Tumor specimens of all included patients (n = 8) before and after the onset of a therapy with somatostatin analogs were analyzed and a micro-RNA expression profile (754 micro-RNAs) of each probe was generated. This analysis in an intra-individual setting was selected to avoid bias from inter-individual differences. The micro-RNA expression profiles were validated by qPCR. Patients with any other systemic treatment were excluded from the present study.
Eight patients were included in the present study of which all had neuroendocrine tumors of the small intestine with diffuse hepatic metastases. Grouped analyses revealed that 15 micro-RNAs were differentially expressed (3 up- and 12 downregulated) after the exposure to somatostatin analogs. Additionally, let-7c-5p and mir-3137 are concordantly regulated in the inter-individually analysis.
This is the first study analyzing the individual micro-RNA expression profile before and after a therapy with somatostatin analogs. Data from this study reveal that somatostatin analogs may in part exert their beneficial effects through an alteration in the micro-RNA expression profile. |
doi_str_mv | 10.1186/s12885-019-5794-y |
format | article |
fullrecord | <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_bfaa50633ae4410c869a948b424da41c</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A590758869</galeid><doaj_id>oai_doaj_org_article_bfaa50633ae4410c869a948b424da41c</doaj_id><sourcerecordid>A590758869</sourcerecordid><originalsourceid>FETCH-LOGICAL-c625t-1b29dbc20e82918056166c233d8a035d61322eaee929c032f7bca944b4ac8ee33</originalsourceid><addsrcrecordid>eNptkl2L1DAUhoso7rr6A7yRgiB60TVfbdMbYVn8GFgQdL0Op8lpJ0PbjEmqO_f-cDM76zoV6UXT9HmfktM3y55Tck6prN4GyqQsC0KboqwbUeweZKdU1LRggtQPj9Yn2ZMQNoTQWhL5ODvhlDYVZfVp9uvaI8QRp5j_tHGdBzdCdCFCtFMOEwyuD7mdzKwx5MZ2HfrEWhiGXY43W48hoMkHjEWti3KbIiYfrS845XXK5WFMaFpEDMmI-YSzdzgZp_3-Mc6j8-Fp9qiDIeCzu_tZ9u3D--vLT8XV54-ry4urQlesjAVtWWNazQhK1lBJyopWlWacGwmEl6ainDEExIY1mnDW1a2GRohWgJaInJ9lq4PXONiorbcj-J1yYNXthvO9Ah-tHlC1HUBJKs4BhaBEy6pJKtkKJgwIqpPr3cG1ndsRjU5T8TAspMs3k12r3v1QVVnVyZIEr-8E3n2f03jUaIPGYYAJ3RwUY4JJymlTJvTlP-jGzT79nFuKMyEp4X-pHtIB7NS59F29l6qLsiF1KdMhEnX-HypdBker3YSdTfuLwJtFIDERb2IPcwhq9fXLkn11xK4RhrgObpijdVNYgvQAau9C8NjdD44Ste-2OnRbpW6rfbfVLmVeHE_8PvGnzPw39V_z9g</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2243248103</pqid></control><display><type>article</type><title>Treatment with somatostatin analogs induces differentially expressed let-7c-5p and mir-3137 in small intestine neuroendocrine tumors</title><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>Bösch, Florian ; Bazhin, Alexandr V ; Heublein, Sabine ; Brüwer, Katharina ; Knösel, Thomas ; Reiter, Florian P ; Auernhammer, Christoph J ; Guba, Markus O ; Spitzweg, Christine ; Werner, Jens ; Angele, Martin K</creator><creatorcontrib>Bösch, Florian ; Bazhin, Alexandr V ; Heublein, Sabine ; Brüwer, Katharina ; Knösel, Thomas ; Reiter, Florian P ; Auernhammer, Christoph J ; Guba, Markus O ; Spitzweg, Christine ; Werner, Jens ; Angele, Martin K</creatorcontrib><description>Distant metastases frequently occur in gastroenteropancreatic neuroendocrine tumors. If hepatic surgery is not feasible, patients are treated with somatostatin analogs. However, the underlying mechanisms of action of this treatment remain to be defined. The aim of the present study was to analyze the micro-RNA expression profile inter-individually before and after the treatment with somatostatin analogs.
Tumor specimens of all included patients (n = 8) before and after the onset of a therapy with somatostatin analogs were analyzed and a micro-RNA expression profile (754 micro-RNAs) of each probe was generated. This analysis in an intra-individual setting was selected to avoid bias from inter-individual differences. The micro-RNA expression profiles were validated by qPCR. Patients with any other systemic treatment were excluded from the present study.
Eight patients were included in the present study of which all had neuroendocrine tumors of the small intestine with diffuse hepatic metastases. Grouped analyses revealed that 15 micro-RNAs were differentially expressed (3 up- and 12 downregulated) after the exposure to somatostatin analogs. Additionally, let-7c-5p and mir-3137 are concordantly regulated in the inter-individually analysis.
This is the first study analyzing the individual micro-RNA expression profile before and after a therapy with somatostatin analogs. Data from this study reveal that somatostatin analogs may in part exert their beneficial effects through an alteration in the micro-RNA expression profile.</description><identifier>ISSN: 1471-2407</identifier><identifier>EISSN: 1471-2407</identifier><identifier>DOI: 10.1186/s12885-019-5794-y</identifier><identifier>PMID: 31196127</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Aged ; Antineoplastic Agents - therapeutic use ; Apoptosis ; Biological Variation, Population ; Biomarkers ; Breast cancer ; Cancer metastasis ; Care and treatment ; Cell growth ; Colorectal cancer ; Female ; Gene expression ; Gene Expression Profiling ; Humans ; Intestinal Neoplasms - drug therapy ; Intestine, Small - pathology ; Intra-individual ; Kinases ; Liver ; Lung cancer ; Lymphatic system ; Male ; Medical research ; Metastases ; Metastasis ; MicroRNA ; MicroRNAs ; MicroRNAs - genetics ; Middle Aged ; Neuroendocrine tumor ; Neuroendocrine tumors ; Neuroendocrine Tumors - drug therapy ; Patients ; Prospective Studies ; Ribonucleic acid ; RNA ; Small intestine ; Somatostatin ; Somatostatin - analogs & derivatives ; Somatostatin - therapeutic use ; Surgery ; Tumors</subject><ispartof>BMC cancer, 2019-06, Vol.19 (1), p.575-575, Article 575</ispartof><rights>COPYRIGHT 2019 BioMed Central Ltd.</rights><rights>2019. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s). 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c625t-1b29dbc20e82918056166c233d8a035d61322eaee929c032f7bca944b4ac8ee33</citedby><cites>FETCH-LOGICAL-c625t-1b29dbc20e82918056166c233d8a035d61322eaee929c032f7bca944b4ac8ee33</cites><orcidid>0000-0002-0250-9017</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6567424/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2243248103?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,724,777,781,882,25734,27905,27906,36993,36994,44571,53772,53774</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31196127$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bösch, Florian</creatorcontrib><creatorcontrib>Bazhin, Alexandr V</creatorcontrib><creatorcontrib>Heublein, Sabine</creatorcontrib><creatorcontrib>Brüwer, Katharina</creatorcontrib><creatorcontrib>Knösel, Thomas</creatorcontrib><creatorcontrib>Reiter, Florian P</creatorcontrib><creatorcontrib>Auernhammer, Christoph J</creatorcontrib><creatorcontrib>Guba, Markus O</creatorcontrib><creatorcontrib>Spitzweg, Christine</creatorcontrib><creatorcontrib>Werner, Jens</creatorcontrib><creatorcontrib>Angele, Martin K</creatorcontrib><title>Treatment with somatostatin analogs induces differentially expressed let-7c-5p and mir-3137 in small intestine neuroendocrine tumors</title><title>BMC cancer</title><addtitle>BMC Cancer</addtitle><description>Distant metastases frequently occur in gastroenteropancreatic neuroendocrine tumors. If hepatic surgery is not feasible, patients are treated with somatostatin analogs. However, the underlying mechanisms of action of this treatment remain to be defined. The aim of the present study was to analyze the micro-RNA expression profile inter-individually before and after the treatment with somatostatin analogs.
Tumor specimens of all included patients (n = 8) before and after the onset of a therapy with somatostatin analogs were analyzed and a micro-RNA expression profile (754 micro-RNAs) of each probe was generated. This analysis in an intra-individual setting was selected to avoid bias from inter-individual differences. The micro-RNA expression profiles were validated by qPCR. Patients with any other systemic treatment were excluded from the present study.
Eight patients were included in the present study of which all had neuroendocrine tumors of the small intestine with diffuse hepatic metastases. Grouped analyses revealed that 15 micro-RNAs were differentially expressed (3 up- and 12 downregulated) after the exposure to somatostatin analogs. Additionally, let-7c-5p and mir-3137 are concordantly regulated in the inter-individually analysis.
This is the first study analyzing the individual micro-RNA expression profile before and after a therapy with somatostatin analogs. Data from this study reveal that somatostatin analogs may in part exert their beneficial effects through an alteration in the micro-RNA expression profile.</description><subject>Aged</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Apoptosis</subject><subject>Biological Variation, Population</subject><subject>Biomarkers</subject><subject>Breast cancer</subject><subject>Cancer metastasis</subject><subject>Care and treatment</subject><subject>Cell growth</subject><subject>Colorectal cancer</subject><subject>Female</subject><subject>Gene expression</subject><subject>Gene Expression Profiling</subject><subject>Humans</subject><subject>Intestinal Neoplasms - drug therapy</subject><subject>Intestine, Small - pathology</subject><subject>Intra-individual</subject><subject>Kinases</subject><subject>Liver</subject><subject>Lung cancer</subject><subject>Lymphatic system</subject><subject>Male</subject><subject>Medical research</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>MicroRNA</subject><subject>MicroRNAs</subject><subject>MicroRNAs - genetics</subject><subject>Middle Aged</subject><subject>Neuroendocrine tumor</subject><subject>Neuroendocrine tumors</subject><subject>Neuroendocrine Tumors - drug therapy</subject><subject>Patients</subject><subject>Prospective Studies</subject><subject>Ribonucleic acid</subject><subject>RNA</subject><subject>Small intestine</subject><subject>Somatostatin</subject><subject>Somatostatin - analogs & derivatives</subject><subject>Somatostatin - therapeutic use</subject><subject>Surgery</subject><subject>Tumors</subject><issn>1471-2407</issn><issn>1471-2407</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNptkl2L1DAUhoso7rr6A7yRgiB60TVfbdMbYVn8GFgQdL0Op8lpJ0PbjEmqO_f-cDM76zoV6UXT9HmfktM3y55Tck6prN4GyqQsC0KboqwbUeweZKdU1LRggtQPj9Yn2ZMQNoTQWhL5ODvhlDYVZfVp9uvaI8QRp5j_tHGdBzdCdCFCtFMOEwyuD7mdzKwx5MZ2HfrEWhiGXY43W48hoMkHjEWti3KbIiYfrS845XXK5WFMaFpEDMmI-YSzdzgZp_3-Mc6j8-Fp9qiDIeCzu_tZ9u3D--vLT8XV54-ry4urQlesjAVtWWNazQhK1lBJyopWlWacGwmEl6ainDEExIY1mnDW1a2GRohWgJaInJ9lq4PXONiorbcj-J1yYNXthvO9Ah-tHlC1HUBJKs4BhaBEy6pJKtkKJgwIqpPr3cG1ndsRjU5T8TAspMs3k12r3v1QVVnVyZIEr-8E3n2f03jUaIPGYYAJ3RwUY4JJymlTJvTlP-jGzT79nFuKMyEp4X-pHtIB7NS59F29l6qLsiF1KdMhEnX-HypdBker3YSdTfuLwJtFIDERb2IPcwhq9fXLkn11xK4RhrgObpijdVNYgvQAau9C8NjdD44Ste-2OnRbpW6rfbfVLmVeHE_8PvGnzPw39V_z9g</recordid><startdate>20190613</startdate><enddate>20190613</enddate><creator>Bösch, Florian</creator><creator>Bazhin, Alexandr V</creator><creator>Heublein, Sabine</creator><creator>Brüwer, Katharina</creator><creator>Knösel, Thomas</creator><creator>Reiter, Florian P</creator><creator>Auernhammer, Christoph J</creator><creator>Guba, Markus O</creator><creator>Spitzweg, Christine</creator><creator>Werner, Jens</creator><creator>Angele, Martin K</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><general>BMC</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>ISR</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-0250-9017</orcidid></search><sort><creationdate>20190613</creationdate><title>Treatment with somatostatin analogs induces differentially expressed let-7c-5p and mir-3137 in small intestine neuroendocrine tumors</title><author>Bösch, Florian ; Bazhin, Alexandr V ; Heublein, Sabine ; Brüwer, Katharina ; Knösel, Thomas ; Reiter, Florian P ; Auernhammer, Christoph J ; Guba, Markus O ; Spitzweg, Christine ; Werner, Jens ; Angele, Martin K</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c625t-1b29dbc20e82918056166c233d8a035d61322eaee929c032f7bca944b4ac8ee33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Aged</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Apoptosis</topic><topic>Biological Variation, Population</topic><topic>Biomarkers</topic><topic>Breast cancer</topic><topic>Cancer metastasis</topic><topic>Care and treatment</topic><topic>Cell growth</topic><topic>Colorectal cancer</topic><topic>Female</topic><topic>Gene expression</topic><topic>Gene Expression Profiling</topic><topic>Humans</topic><topic>Intestinal Neoplasms - drug therapy</topic><topic>Intestine, Small - pathology</topic><topic>Intra-individual</topic><topic>Kinases</topic><topic>Liver</topic><topic>Lung cancer</topic><topic>Lymphatic system</topic><topic>Male</topic><topic>Medical research</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>MicroRNA</topic><topic>MicroRNAs</topic><topic>MicroRNAs - genetics</topic><topic>Middle Aged</topic><topic>Neuroendocrine tumor</topic><topic>Neuroendocrine tumors</topic><topic>Neuroendocrine Tumors - drug therapy</topic><topic>Patients</topic><topic>Prospective Studies</topic><topic>Ribonucleic acid</topic><topic>RNA</topic><topic>Small intestine</topic><topic>Somatostatin</topic><topic>Somatostatin - analogs & derivatives</topic><topic>Somatostatin - therapeutic use</topic><topic>Surgery</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bösch, Florian</creatorcontrib><creatorcontrib>Bazhin, Alexandr V</creatorcontrib><creatorcontrib>Heublein, Sabine</creatorcontrib><creatorcontrib>Brüwer, Katharina</creatorcontrib><creatorcontrib>Knösel, Thomas</creatorcontrib><creatorcontrib>Reiter, Florian P</creatorcontrib><creatorcontrib>Auernhammer, Christoph J</creatorcontrib><creatorcontrib>Guba, Markus O</creatorcontrib><creatorcontrib>Spitzweg, Christine</creatorcontrib><creatorcontrib>Werner, Jens</creatorcontrib><creatorcontrib>Angele, Martin K</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>BMC cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bösch, Florian</au><au>Bazhin, Alexandr V</au><au>Heublein, Sabine</au><au>Brüwer, Katharina</au><au>Knösel, Thomas</au><au>Reiter, Florian P</au><au>Auernhammer, Christoph J</au><au>Guba, Markus O</au><au>Spitzweg, Christine</au><au>Werner, Jens</au><au>Angele, Martin K</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment with somatostatin analogs induces differentially expressed let-7c-5p and mir-3137 in small intestine neuroendocrine tumors</atitle><jtitle>BMC cancer</jtitle><addtitle>BMC Cancer</addtitle><date>2019-06-13</date><risdate>2019</risdate><volume>19</volume><issue>1</issue><spage>575</spage><epage>575</epage><pages>575-575</pages><artnum>575</artnum><issn>1471-2407</issn><eissn>1471-2407</eissn><abstract>Distant metastases frequently occur in gastroenteropancreatic neuroendocrine tumors. If hepatic surgery is not feasible, patients are treated with somatostatin analogs. However, the underlying mechanisms of action of this treatment remain to be defined. The aim of the present study was to analyze the micro-RNA expression profile inter-individually before and after the treatment with somatostatin analogs.
Tumor specimens of all included patients (n = 8) before and after the onset of a therapy with somatostatin analogs were analyzed and a micro-RNA expression profile (754 micro-RNAs) of each probe was generated. This analysis in an intra-individual setting was selected to avoid bias from inter-individual differences. The micro-RNA expression profiles were validated by qPCR. Patients with any other systemic treatment were excluded from the present study.
Eight patients were included in the present study of which all had neuroendocrine tumors of the small intestine with diffuse hepatic metastases. Grouped analyses revealed that 15 micro-RNAs were differentially expressed (3 up- and 12 downregulated) after the exposure to somatostatin analogs. Additionally, let-7c-5p and mir-3137 are concordantly regulated in the inter-individually analysis.
This is the first study analyzing the individual micro-RNA expression profile before and after a therapy with somatostatin analogs. Data from this study reveal that somatostatin analogs may in part exert their beneficial effects through an alteration in the micro-RNA expression profile.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>31196127</pmid><doi>10.1186/s12885-019-5794-y</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0002-0250-9017</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1471-2407 |
ispartof | BMC cancer, 2019-06, Vol.19 (1), p.575-575, Article 575 |
issn | 1471-2407 1471-2407 |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_bfaa50633ae4410c869a948b424da41c |
source | Publicly Available Content Database; PubMed Central |
subjects | Aged Antineoplastic Agents - therapeutic use Apoptosis Biological Variation, Population Biomarkers Breast cancer Cancer metastasis Care and treatment Cell growth Colorectal cancer Female Gene expression Gene Expression Profiling Humans Intestinal Neoplasms - drug therapy Intestine, Small - pathology Intra-individual Kinases Liver Lung cancer Lymphatic system Male Medical research Metastases Metastasis MicroRNA MicroRNAs MicroRNAs - genetics Middle Aged Neuroendocrine tumor Neuroendocrine tumors Neuroendocrine Tumors - drug therapy Patients Prospective Studies Ribonucleic acid RNA Small intestine Somatostatin Somatostatin - analogs & derivatives Somatostatin - therapeutic use Surgery Tumors |
title | Treatment with somatostatin analogs induces differentially expressed let-7c-5p and mir-3137 in small intestine neuroendocrine tumors |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T00%3A32%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20with%20somatostatin%20analogs%20induces%20differentially%20expressed%20let-7c-5p%20and%20mir-3137%20in%20small%20intestine%20neuroendocrine%20tumors&rft.jtitle=BMC%20cancer&rft.au=B%C3%B6sch,%20Florian&rft.date=2019-06-13&rft.volume=19&rft.issue=1&rft.spage=575&rft.epage=575&rft.pages=575-575&rft.artnum=575&rft.issn=1471-2407&rft.eissn=1471-2407&rft_id=info:doi/10.1186/s12885-019-5794-y&rft_dat=%3Cgale_doaj_%3EA590758869%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c625t-1b29dbc20e82918056166c233d8a035d61322eaee929c032f7bca944b4ac8ee33%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2243248103&rft_id=info:pmid/31196127&rft_galeid=A590758869&rfr_iscdi=true |